Latest News February 12, 2008 - Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech December 20, 2007 - Altor BioScience Advances Clinical Trial for Targeted Cancer Therapeutic, ALT-801 July 25, 2006 - Altor BioScience Awarded Phase II SBIR Grant for Anti-Cancer Antibody Manufacture in Transgenic Plants More News...

Technology The Company’s proprietary Soluble T-cell Antigen Receptor (STAR™) technology enables the recognition of novel targets on cancerous or virally infected cells which cannot be seen by traditional monoclonal antibodies. More on Altor’s Technology... Product/Clinical Development Altor’s lead anti-cancer STAR™ fusion product, 264scTCR-IL2, or ALT-801, is a soluble T-cell receptor fused with the cytokine IL2, which targets cancer cells expressing the tumor-associated antigen, p53. ALT-801 has advanced to a Phase I/IIa clinical trial. More on Product/Clinical Development...

Research Reagents Altor has launched an exciting new class of innovative products based on its proprietary STAR™ technology. These products enable the detection of novel disease targets presented on the surface of cells and tissues. Altor has also introduced recombinant human tissue factor for use in hemostasis and thrombosis research applications. More on Research Reagents...